Arkansas 2024 Regular Session

Arkansas House Bill HR1003 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2	DTP242 3/21/2024 9:48:19 AM DTP242
3	3
4	4	State of Arkansas 1
5	5	94th General Assembly 2
6	6	Fiscal Session, 2024 HR 1003 3
7	7	4
8	8	By: Representative C. Fite 5
9	9	6
10	10	HOUSE RESOLUTION 7
11	11	TO DESIGNATE MAY 5-11, 2024 AS "TARDIVE DYSKINESIA 8
12	12	AWARENESS WEEK". 9
13	13	10
14	14	11
15	15	Subtitle 12
16	16	TO DESIGNATE MAY 5-11, 2024 AS "TARDIVE 13
17	17	DYSKINESIA AWARENESS WEEK". 14
18	18	15
19	19	16
20	20	WHEREAS, many people living with serious mental illnesses or 17
21	21	gastrointestinal disorders may be treated with medications that work as 18
22	22	dopamine receptor blocking agents, including antipsychotics and antiemetics; 19
23	23	and 20
24	24	21
25	25	WHEREAS, while ongoing treatment with these medications can be 22
26	26	necessary, prolonged use is associated with tardive dyskinesia (TD), an 23
27	27	involuntary movement disorder that is characterized by uncontrollable, 24
28	28	abnormal, and repetitive movements of the face, torso, limbs, and fingers or 25
29	29	toes; and 26
30	30	27
31	31	WHEREAS, even mild symptoms of tardive dyskinesia (TD) can impact 28
32	32	people physically, socially, and emotionally; and 29
33	33	30
34	34	WHEREAS, it is estimated that tardive dyskinesia (TD) affects 31
35	35	approximately six hundred thousand (600,000) people in the United States and 32
36	36	approximately sixty-five percent (65%) of people with tardive dyskinesia (TD) 33
37	37	have not been diagnosed, making it important to raise awareness about the 34
38	38	symptoms of tardive dyskinesia (TD); and 35
39	39	36 HR1003
40	40
41	41	2 3/21/2024 9:48:19 AM DTP242
42	42
43	43
44	44	WHEREAS, it is important that people taking medicines that work as 1
45	45	dopamine receptor blocking agents be monitored for tardive dyskinesia (TD) by 2
46	46	a healthcare provider as recommended by the American Psychiatric Association; 3
47	47	and 4
48	48	5
49	49	WHEREAS, clinical research has led to the approval of certain 6
50	50	treatments for adults with tardive dyskinesia (TD) by the U.S. Food and Drug 7
51	51	Administration; and 8
52	52	9
53	53	WHEREAS, recognition and treatment of tardive dyskinesia (TD) can make 10
54	54	a positive impact in the lives of many people experiencing this side effect 11
55	55	from taking medications that work as dopamine receptor blocking agents; and 12
56	56	13
57	57	WHEREAS, the General Assembly can raise awareness of tardive 14
58	58	dyskinesia (TD) among the public and medical community, 15
59	59	16
60	60	NOW THEREFORE, 17
61	61	BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE NINETY -FOURTH GENERAL 18
62	62	ASSEMBLY OF THE STATE OF ARKANSAS: 19
63	63	20
64	64	THAT the House of Representatives: 21
65	65	(1) designate May 5 -11, 2024 as "Tardive Dyskinesia Awareness Week"; 22
66	66	and 23
67	67	(2) encourage anyone experiencing uncontrollable, abnormal, and 24
68	68	repetitive movements to consult their healthcare provider regarding their 25
69	69	symptoms. 26
70	70	27
71	71	28
72	72	29
73	73	30
74	74	31
75	75	32
76	76	33
77	77	34
78	78	35
79	79	36